OQY-3258, also known as ESG401, is an anti-TROP2 ADC currently under evaluation in three clinical trials: A Phase 1a/1b clinical trial for patients with solid tumors (NCT04892342). A Phase 3 study in ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.DN-d7ZPu.js ...
Antibody Therapy MarketThe global antibody therapy market is on a strong growth trajectory, projected to expand at a CAGR of ...
The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...
Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...
News Medical on MSN16h
Exploring the interaction between cell death and cellular senescence in cancerAging cells secrete substances known to promote the growth of cancer cells. The development of drugs that can selectively kill these cells or inhibit the secretion of substances is ongoing.
Robert F. Kennedy Jr. may soon be America's top pharmaceutical regulator. That is cause for concern in Seattle’s biotech ...
A third drug, pretomanid, received emergency authorization from the FDA for specific use within a regimen against highly drug ...
The field of cancer treatment is witnessing rapid advancements due to progress in proteomics, genomics, and drug discovery. These technologies have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback